therapeutically in Th2-mediated autoimmune and allergic disorders. Therefore, the effect of systemic IL-12 treatment on in vivo autoantibody synthesis in hepatitis B e antigen (HBeAg)-expressing transgenic mice, which is dependent on self-reactive Th2 cells, was examined. Low-dose IL-12 significantly inhibited autoantibody production by shifting the Th2-mediated response toward Th1 predominance. Additionally, previous studies suggest that a predominance of HBeAgspecific Th2-type cells may contribute to chronicity in hepatitis B virus infection. Therefore, IL-12 may also prove beneficial in modulating the HBeAg-specific Th response to favor viral clearance in chronic hepatitis B virus infection.
Distinct subsets of regulatory CD4+ helper T (Th) cells designated as Th1 and Th2 cells have been defined (1) . The Th subsets are largely defined by unique patterns of cytokine secretion such that Th1 cells produce interleukin (IL)-2, interferon y (IFN-,y), and tumor necrosis factor 03 (TNF,B), whereas Th2 cells produce IL-4, IL-5, IL-6, IL-10, and IL-13 (2) . The differences in cytokine secretion account for the functional dichotomy between Th, cells, which mediate cellular immunity, and Th2 cells, which enhance humoral immunity. In addition to mediating effector functions, cytokines appear to exert a dominant influence on the differentiation of T cells into the Th1 or Th2 subset. For example, is essential for the differentiation of Th2 cells and blocks development of Th1 cells (3, 4) , whereas IL-12 enhances Th, cell development and diminishes Th2 cell induction largely through stimulation of IFN-,y production (5, 6) . Furthermore, cytokines also influence the isotype of antibody produced. Human and murine IgE and murine IgG, responses are promoted by IL-4, and IFN-,y enhances murine IgG2a responses (7) .
The clinical significance of distinct Th1 and Th2 phenotypes first emerged from studies of parasitic infections. These studies revealed that specific pathogens may be more effectively controlled by a predominant Th1-or Th2-type immune response (8) (9) (10) (11) .
These previous studies suggest that, in addition to the treatment of parasitic infections, IL-12 may be useful therapeutically in antibody-mediated autoimmune disorders and allergies in which Th2-like responses may dominant (12, 13) . We utilized a transgenic (Tg) model of autoantibody production to examine the effects of IL-12 on an autoimmune process (14) . In this model, hepatitis B e antigen (HBeAg)-expressing Tg mice on a specific major histocompatibility complex (MHC) background can be induced to produce autoantibody (anti-HBe) by the injection of a T-cell recognition site that fails to elicit T-cell
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. tolerance in these mice. Hemizygous Tg3le mice secrete HBeAg into the circulation at a concentration of 10 ng/ml (15) . Th Autoantibody production is maximal 3 weeks after the 129-140 injection and slowly declines thereafter. Serum HBeAg levels decline in parallel with increased autoantibody production due to immune complex formation (see Fig. 1B ; PBS control). The aim of this studywas to examine the effects of rIL-12 treatment on the induction of this autoantibody response, on established autoantibody production, and on the phenotype of the Th cells regulating the autoimmune response.
MATERIALS AND METHODS
Tg Mice. The Tg mouse lineage designated BIO.S-Tg3le, which expresses HBeAg (9-13 ng/ml) in the serum, was produced as described (15 14 (Fig. 1A) . The minimum rIL-12 required to significantly inhibit autoantibody production when given during this early time frame was a total dose of 2.0 jig (data not shown). Initiation of the rIL-12 treatment at a later timne [days [8] [9] [10] [11] [12] ; IL-12(2) group] was less effective than early treatment but nevertheless inhibited autoantibody production by approximately 16-fold from week 2 through week 7 (Fig. 1A) . However, autoantibody production was inhibited to the greatest degree (a 256-fold or greater reduction in IgG autoantibody titer relative to the control from week 2 through week 7) when 1 (Fig. 3) . In the context of ongoing autoantibody production, IL-12 had minimal effects during the first 2 weeks of treatment (i.e., 4 (Fig. 3A) . The serum HBeAg levels were inversely related to autoantibody production in both groups, and serum HBeAg concentrations were significantly higher in the IL-12 treatment group at weeks 7 and 9 (Fig. 3B) Fl-Tg3le (e/+) recipient mice, which were then analyzed for anti-HBe antibody production (Fig. 4) . Because treatment with IL-2 and with no cytokine supplement yielded similar results, the control data are not shown. Although peptide 120-131 elicits strong HBeAg-specific T-cell proliferative responses and efficient IL-2 and IFN-y production (18), it primes T-cell helper function for antibody production relatively poorly even in the presence of IL-2 during the culture phase (Fig. 4 Upper). In contrast, peptide 129-140 elicits weak HBeAgspecific T-cell proliferative responses and poor IL-2 and IFN-,y production (18), yet primes Th cell function very efficiently.
Transfer of 129-140-primed Th cells into Fl-Tg3le recipient mice resulted in high titer autoantibody production which reduced serum HBeAg levels (Fig. 4 
DISCUSSION
These studies revealed that relatively low-dose systemic treatment with rIL-12 can significantly suppress autoantibody production in vivo. The mechanism of autoantibody inhibition appears related to the ability of IL-12 to enhance Th1-associated cytokine production (IFN-'y) and inhibit Th2-associated cytokine production . Therefore, the large number of autoimmune and allergic disorders that are believed to be mediated by Th2-type cells may be amenable to treatment with IL-12. Furthermore, the observations that ongoing autoantibody production was susceptible to inhibition by and that incubation of mature (22) .
Last, this study highlights this unique transgenic model of autoimmunity in which autoantibody production, autoantigen clearance from the serum, and the phenotype of the selfreactive Th cells can all be determined within 2-3 weeks with a simple blood sample. This model should be useful to screen a variety of immunomodulatory drugs or therapies.
